Compare WEN & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEN | AAPG |
|---|---|---|
| Founded | 1969 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2001 | 2024 |
| Metric | WEN | AAPG |
|---|---|---|
| Price | $8.61 | $13.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 11 |
| Target Price | $8.04 | ★ $44.50 |
| AVG Volume (30 Days) | ★ 7.3M | 5.3K |
| Earning Date | 11-05-2026 | 08-19-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,176,891,000.00 | N/A |
| Revenue This Year | $1.71 | $17.91 |
| Revenue Next Year | $0.57 | $111.96 |
| P/E Ratio | $23.24 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.94 | $12.44 |
| 52 Week High | $9.45 | $33.09 |
| Indicator | WEN | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 68.64 | 28.86 |
| Support Level | $6.62 | N/A |
| Resistance Level | $9.30 | $16.28 |
| Average True Range (ATR) | 0.34 | 0.38 |
| MACD | 0.07 | -0.27 |
| Stochastic Oscillator | 77.57 | 0.26 |
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.